Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$5.91 USD
+0.30 (5.35%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.91 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Cash flow Statements
Fiscal Year End for Corvus Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -27.03 | -41.31 | -43.24 | -6.00 | -46.67 |
Depreciation/Amortization & Depletion | -0.74 | 0.20 | 0.70 | 0.79 | 0.10 |
Net Change from Assets/Liabilities | -3.59 | 1.41 | -3.24 | 1.91 | 1.90 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 7.43 | 12.68 | 9.06 | -31.48 | 7.35 |
Net Cash From Operating Activities | -23.94 | -27.02 | -36.72 | -34.78 | -37.32 |
Property & Equipment | -0.03 | -0.25 | -0.01 | -0.08 | -0.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 15.58 | -23.03 | 21.57 | 44.85 | 3.28 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 15.54 | -23.28 | 21.56 | 44.77 | 3.26 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.01 | 0.00 | 60.94 | 1.22 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 7.84 | 0.00 | 1.22 | 0.09 | 0.02 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 7.86 | 0.00 | 62.16 | 1.31 | 0.02 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -0.54 | -50.30 | 47.00 | 11.30 | -34.04 |
Cash at Beginning of Period | 13.16 | 63.46 | 16.46 | 5.15 | 39.20 |
Cash at End of Period | 12.62 | 13.16 | 63.46 | 16.46 | 5.15 |
Diluted Net EPS | -0.56 | -0.89 | -1.03 | -0.20 | -1.59 |
Fiscal Year End for Corvus Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -9.96 | -5.70 | -27.03 | -20.38 | -14.38 |
Depreciation/Amortization & Depletion | -0.33 | -0.13 | -0.74 | -0.64 | -0.43 |
Net Change from Assets/Liabilities | -0.33 | 0.22 | -3.59 | -3.20 | -2.57 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -0.02 | 0.45 | 7.43 | 5.46 | 4.04 |
Net Cash From Operating Activities | -10.64 | -5.16 | -23.94 | -18.77 | -13.33 |
Property & Equipment | 0.00 | 0.00 | -0.03 | -0.03 | -0.03 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -17.51 | -0.01 | 15.58 | 17.89 | 0.35 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -17.51 | -0.01 | 15.54 | 17.86 | 0.31 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 30.37 | 0.00 | 0.01 | 7.84 | 7.52 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 7.84 | 0.01 | 0.00 |
Other Financing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 30.37 | 0.00 | 7.86 | 7.86 | 7.52 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 2.22 | -5.16 | -0.54 | 6.95 | -5.50 |
Cash at Beginning of Period | 12.62 | 12.62 | 13.16 | 13.16 | 13.16 |
Cash at End of Period | 14.84 | 7.46 | 12.62 | 20.11 | 7.66 |
Diluted Net EPS | -0.07 | -0.12 | -0.13 | -0.12 | -0.14 |